{"product_id":"heart-in-diabetes-8th-annual-heart-in-diabetes-conference-2024","title":"Heart in Diabetes 8th Annual Heart in Diabetes Conference 2024","description":"\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-id=\"bbb44b8\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\r\n\u003cdiv id=\"m_0_0_0\" class=\"epi-mod-drg epi-portlet-locked\"\u003e\r\n\u003cdiv class=\"row\"\u003e\u003csection class=\"content-standard content-default standard\"\u003e\r\n\u003cdiv class=\"content-header\"\u003e\r\n\u003cdiv class=\"row\"\u003e\r\n\u003cdiv id=\"m_0_0_0\" class=\"epi-mod-drg epi-portlet-locked\"\u003e\r\n\u003cdiv class=\"row\"\u003e\u003csection class=\"content-standard content-default standard\"\u003e\r\n\u003cdiv class=\"content-header\"\u003e\r\n\u003cdiv class=\"row\"\u003e\r\n\u003ch3 class=\"product-title product_title entry-title\"\u003eHeart in Diabetes 8th Annual Heart in Diabetes Conference 2024\u003c\/h3\u003e\r\n\u003cdiv class=\"form-group\"\u003e\r\n\u003cdiv class=\"form-control-plaintext\"\u003e\r\n\u003cdiv class=\"form-group\"\u003e\r\n\r\nHeart in Diabetes\r\n\r\n\u003cstrong\u003e Include: 44 videos, size: 11.3 GB\u003c\/strong\u003e\r\n\r\nHeart in Diabetes 8th Annual Heart in Diabetes (HiD) CME Conference is organized by The Metabolic Institute of America (TMIOA) and will be held from Jun 07 – 09, 2024 at Hilton Philadelphia at Penn’s Landing, Philadelphia, Pennsylvania, United States of America.\r\n\r\nHeart in Diabetes\r\n\r\n\u003cstrong\u003eLearning Objectives:\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eUpon completion of this meeting, participants should be able to:\u003c\/strong\u003e\r\n\r\n• Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome.\r\n\r\n• Be able to assess cardiovascular risk in diabetes.\r\n\r\n• Describe the different etiologies of cardiomyopathies.\r\n\r\n• Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia as well as hyperglycemia.\r\n\r\n• Describe optimal use of technology—specifically CGM—and digital technology and their impact on diabetes and CVD\r\n\r\n• Be able to recognize and manage hypoglycemia and its impact on comorbidities\r\n\r\n• Evaluate stroke in diabetes and cardiorenal metabolic disease\r\n\r\n• Be able to evaluate prevent and manage atherosclerosis and ASCVD\r\n\r\n• Recognize the full spectrum of Heart Failure dictating approach to management\r\n\r\n• Know GDMT in the 4 Pillar management of HFrEF\r\n\r\n• Develop contemporary management of HFpEF\r\n\r\n• Discuss the impact of obesity and diets on fatty liver, CKD, CVD, and HF\r\n\r\n• Evaluate the evidence supporting the use of GLP1-RAs, SGLT inhibitors, nonsteroidal MRAs, and other treatments to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D\r\n\r\n• Describe new and evolving agents in dyslipidemia treatment and how they can be used to reduce ASCVD\r\n\r\n• Explain the important role of Lp(a) in the development atherosclerosis\r\n\r\n• Understand the potential role and impact of AHA Presidential Advisory on Cardio-Kidney-Metabolic Health\r\n\r\n• Discuss the changes in diagnosis and management based on DCRM 2.0 Global Multispecialty Practice Recommendations\r\n\r\n• Evaluate the impact on clinical practice of new CVOTs, including those evaluating antihyperglycemic, lipid-lowering, and other medications such as nonsteroidal MRAs and anticoagulation therapies\r\n\r\n• Understand the role of GLP1-RAs in prevention of CVD, strokes, and CKD in diabetes and obesity\r\n\r\n• Describe the state of heart disease in women\r\n\r\n• Discuss diabetes, CKD, CVD, and HF in diverse populations\r\n\r\n• Develop treatment plans to prevent and manage CKD and its complications with ACE\/ARB, SGLT inhibitors, finerenone, and GLP1-RAs in combination.\r\n\r\nHeart in Diabetes\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"col-md-12 pb-4 mb-3 target-audience-section\"\u003e\r\n\u003cp class=\"detail-title\"\u003e\u003cstrong\u003eTARGET AUDIENCE\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cspan class=\"target-audience-item align-items-center\"\u003eHeart in Diabetes\u003c\/span\u003e\r\n\r\n\u003cspan class=\"target-audience-item align-items-center\"\u003ePharmacist, Physician Assistant, Diabetologists, Cardiologists, Family Physicians, Nephrologists, Residents, Nurses, Internist, Dietitian, Medical Students, Endocrinologist, Nurse Practitioners, Fellows, Other health Professionals\u003c\/span\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"col-md-12 pb-4 mb-3 specialities-section\"\u003e\r\n\u003cp class=\"detail-title\"\u003e\u003cstrong\u003eSPECIALITIES\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cspan class=\"specialities-item align-items-center\"\u003eEndocrinology, Metabolism and Diabetes, Cardiology\u003c\/span\u003e\r\n\r\n\u003c\/div\u003e\r\nHeart in Diabetes\r\n\r\n\u003cstrong\u003e Topics:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAHA CKM Health Initiative The Nephrology Perspective.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAn Overview of Cardiovascular-Kidney-Metabolic (CKM) Health.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAtherothrombotic Risk Stratification in Patients With Type 2 Diabetes.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBeyond 10-Year Risk New Paradigms for Long-Term Risk Estimation With AHA PREVENT.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCardiovascular Disease in the Very Old.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCardiovascular Outcomes in GRADE – The Impact of Antihyperglycemic Agents in Lower Risk Patients With Type 2 Diabetes.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eClinical Interventions in Atherosclerosis.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCRM in Amyloidosis.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDiabetic Foot Ulcers in the Cardiovascular Patient Population An AHA Scientific Statement.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eEradicating Atherosclerotic Events by Targeting Early Subclinical Disease.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eEstimated Lifetime Benefits of SGLT2i, GLP-1RA, and Non-Steroidal MRAs in People With Type 2 Diabetes and Albuminuria.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eExercise in Diabetes Care – From CV Outcomes to Longevity.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eFLOW – The First Dedicated CKD Outcomes Trial With a GLP-1 Receptor Agonist.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eFunctional Hypothalamic Amenorrhea Consequences Beyond the Menstrual Cycle.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGestational Diabetes and Future Cardiovascular Disease in Women.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGLP1-RA and Risk of Stroke.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGuideline Recommended Therapy in Patients With Diabetic Kidney Disease.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHDL-C Helpful, Harmful, Hopeful, or Guilty by Association.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHeart Failure Post Myocardial Infraction and Valvular Disease.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHypertension and Hyperglycemia Twin Sisters Masquerading as Cushing Syndrome.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHypertension Awakenings Finally Something New to Talk About.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eImpact of Cumulative Risk Factor Exposure on Incident Cardiovascular Disease.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eIntegrating Wearables, Behavior and AI to Improve Metabolic Health.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eKetone Metabolism and the Human Heart Implications for Heart Failure.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eLp(a) in ASCVD – What We Know, Should Know and Want to Know.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMedical Treatment of Hypercortisolism With Relacorilant Final Results of the Phase 3 GRACE Study.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMetabolic Dysfunction Associated Steatohepatitis Advancing the Understanding of Underlying Mechanisms, Diagnostic Approach and Therapeutic Strategies.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eModifying Cardiovascular Risk Associated With CKD in T2D With Finerenone.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eNew Emerging Treatment for DKD.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eNew Targets and Upcoming Medications for Dyslipidemia.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eOptimal Strategy for HF Screening Among Adults With Diabetes Without ASCVD A Pooled Cohort Analysis.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eOutcome of Advanced CKD Without Albuminuria Impact of SGLT2i and GLP-1 RA.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePredicting and Preventing Hospital Admissions in Patients With Heart Failure It’s Really Difficult.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSELECT GLP1 RA Impact on ASCVD in Obesity Without Diabetes.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSimultaneous vs. Sequential Start of Foundation Therapies in CKD.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSocial Isolation, Loneliness, and Diabetes.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eStroke vs. CAD Disparities in Risk Factor Management.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTechnology in the Management of Diabetes.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Contemporary Management of Heart Failure.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Different Etiologies of Cardiomyopathy.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Dynamic Duo GLP-1 Receptor Agonists and SGLT2 Inhibitors.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Multiplying Effect of T2D With CKD on the Spectrum of Heart Disease and Mortality.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Proper Management of a Patient With Heart Failure Circa 2024.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eWhen Weight is a Barrier to Transplant Managing Obesity in Patients With Advanced HF.mp4\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/section\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/section\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954561912930,"sku":"MED-AMB06127","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Heart-in-Diabetes-8th-Annual-Heart-in-Diabetes-Conference-2024.webp?v=1779379750","url":"https:\/\/meducourse.com\/products\/heart-in-diabetes-8th-annual-heart-in-diabetes-conference-2024","provider":"Meducourse","version":"1.0","type":"link"}